![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » LifeCycle Pharma Successfully Completes EUR 15 Million Financing
LifeCycle Pharma Successfully Completes EUR 15 Million Financing
May 18, 2005
LifeCycle Pharma A/S announced that it has successfully completed a EUR 15 million private placement. The Series C round was led by Alta Partners, a major U.S.-based life science investor active in both Europe and North America. DG Lux Multimanager I Sicav Lacuna Apo BioTech Subfund, a fund advised by Adamant Biomedical Investments AG (Switzerland), together with all existing investors H. Lundbeck A/S, Novo A/S and Nordic Biotech participated in the round. Dr. Jean Deleage, co-founder and director of Alta Partners, will join LifeCycle Pharma's board of directors.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct